🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

COVID-19 vaccine negotiations: EU watchdog questions Commission’s stance over text messages #covid19 European Ombudsman Pfizer Inc. #vaccine #CovidVaccine biopharma-reporter.com/Article/2022/0…

Synthego breaks ground on sgRNA manufacturing facility. The company plans to use the additional capacity to manufacture synthetic sgRNAs, used in the development of CRISPR-mediated cell and #gene therapies. Synthego #GeneTherapy #celltherapy #CRISPR biopharma-reporter.com/Article/2022/0…

Join us next week for our free-to-attend webinar on Bioprocessing 4.0! Register here: onlinexperiences.com/Launch/QReg/Sh…

Join us tomorrow for our free-to-attend webinar, Bioprocessing 4.0! Register here: onlinexperiences.com/scripts/Server…

It's today! Join us for our free webinar on bioprocessing 4.0. Find out about what today's smart factory looks like; the role bioprocessing 4.0 has to play in the current energy crisis - and much more. Register here to listen live or on-demand. onlinexperiences.com/scripts/Server…

.AstraZeneca and @SanofiScience secure EU approval for antibody to prevent RSV in infants biopharma-reporter.com/Article/2022/1…

Earnings miss, lowered outlook for Catalent Pharma biopharma-reporter.com/Article/2022/1…

From the #BIO2023 floor: we spoke to Cytiva CEO Emmanuel Ligner about how the company's recent integration with @PallBiotech is a "winning recipe" and how Cytiva is staying plugged into the industry... biopharma-reporter.com/Article/2023/0…

Fantastic to speak with Anebulo Pharmaceuticals's Simon Allen at Bio Boston about the rise of acute cannabinoid intoxication and the company's promising new drug to treat it... outsourcing-pharma.com/Article/2023/0…

A pleasure to speak with Lucy Jung, CEO of Charco, about the company's innovative wearable device, her career background and fascination for problem-solving... biopharma-reporter.com/Article/2023/0…

While global biopharma firm Takeda used to be 'entirely reliant' on its CRO partners, the company is now striving to take control of its technology. Penny Carlson outlined the strategy at Veeva Systems' R&D and Quality summit... biopharma-reporter.com/Article/2023/0… #takeda #veeva

🚨 BREAKING NEWS: Sharp Packaging has acquired Berkshire Sterile Manufacturing to offer a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry. biopharma-reporter.com/Article/2023/1…

Our first podcast of 2023 with Dr Sarah Bateup, therapy lead at Clerkenwell Health... biopharma-reporter.com/Article/2023/1…

Weight loss drugs dominated the conversation at Jefferies London Healthcare Conference. Read our recap of a panel discussing how CDMO's are approaching the market and getting ahead of the curve... biopharma-reporter.com/Article/2023/1…

Watch: Bio Pharma Reporter hosted a fascinating conversation at Phacilitate's Advanced Therapies Week - with speakers from @OrganaBio, TrakCel, Catalent Pharma. biopharma-reporter.com/Article/2024/0…

Big news for the pharma industry. A net positive or negative? biopharma-reporter.com/Article/2024/0…

Professor Luigi, of the San Raffaele Telethon Institute for Gene Therapy in Milan, tells us about his fascinating career in gene therapy... biopharma-reporter.com/Article/2024/0…

Maya Martinez-Davis, president, US commercial at GSK , outlined her approach to senior leadership Reuters Events Pharma biopharma-reporter.com/Article/2024/0…

Whether they recognise it or not, the entire pharma industry is involved in the business of health equity and championing it is critically important, Reshema Kemps-Polanco CCO of Novartis told Reuters Events Pharma in her brilliant talk. biopharma-reporter.com/Article/2024/0…

Pfizer has received a slap on the wrist from the Prescription Medicines Code of Practice Authority but how much damage has this done and will it trigger internal changes at the pharma giant? Read our analysis biopharma-reporter.com/Article/2024/0…